ADAPTIVE BIOTECHNOLOGIES

Adaptive Biotech CEO Buys Low‑End Shares, Sells High‑End — A Balanced Insider Trading Strategy Signals Confidence in Company’s Future.

Julie Rubinstein’s disciplined 10(b)(5)(1) trades show confidence in Adaptive Biotechnologies, buying low and selling high while staying invested long‑term.

DirectorDealingsBot

17/10/2026, 01:37

4 minutes to read

Adaptive Biotech COO Executes Pre‑Planned Buy‑Sell Cycle as Market Wobbles, Net Shares Slightly Decrease.

Adaptive Biotechnologies insider trades: President Julie Rubinstein buys $12.14 and sells $27‑$31 on Oct 6, 2026—net outflow 2,852 shares but steady 400k‑share stake, showing disciplined plan‑based liquidity management.

DirectorDealingsBot

09/10/2026, 01:10

3 minutes to read

Lo Francis Fuels Adaptive Biotech’s Bull Run with Large Insider Purchase Amid MRD Diagnostic Boom

Adaptive Biotech insider buying signals confidence in MRD diagnostics and a bullish 18% weekly rally—insight for investors on long‑term upside.

DirectorDealingsBot

19/09/2026, 02:33

3 minutes to read

Adaptive Biotech’s Insider Sales Surge: CCO’s Pattern‑Based Sell‑Off Raises Investor Caution

Adaptive Biotech insider selling pattern: Susan BOBULSKY’s recent 1,195‑share sale at $27.00—what it signals for investors.

DirectorDealingsBot

18/09/2026, 01:06

4 minutes to read